Research at Korea Research Institute of Chemical Technology (KRICT) has led to the identification of pyrazolopyrimidine-containing compounds acting as dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors and reported to be useful for the treatment of cancer.
858 Therapeutics Inc. has patented a series of 6,6-fused heterocyclic compounds acting as N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
Atai Life Sciences AG has described 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
Beigene Co. Ltd. has divulged antibody-drug conjugates (ADC) comprising HER3 (erbB3) targeting antibody linked to an effector molecule through a linker reported to be useful for the treatment of cancer, metabolic diseases, neurodegeneration and inflammation.
Hangzhou Adamerck Pharmlabs Inc. has disclosed uracil derivatives reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
Astellas Pharma Inc. has divulged substituted quinolone derivates acting as acetylcholine receptor cluster inducers reported to be useful for the treatment of neuromuscular disorders.
RSS
